Novan Inc
F:6LUA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
N
|
Ningbo KBE Electrical Technology Co Ltd
SZSE:300863
|
CN |
|
OFS Capital Corp
NASDAQ:OFS
|
US |
|
H
|
Hemang Resources Ltd
BSE:531178
|
IN |
|
IFCI Ltd
BSE:500106
|
IN |
|
E
|
EDP Energias de Portugal SA
ELI:EDP
|
PT |
|
D
|
Dalipal Holdings Ltd
HKEX:1921
|
CN |
|
Arm Holdings PLC
NASDAQ:ARM
|
UK |
|
K
|
Karbon-X Corp
OTC:KARX
|
CA |
|
Yu Tak International Holdings Ltd
HKEX:8048
|
HK |
|
Visual China Group Co Ltd
SZSE:000681
|
CN |
|
C
|
Calgro M3 Holdings Ltd
JSE:CGR
|
ZA |
|
M
|
Mediatechnics Corp
OTC:MEDT
|
US |
|
Getlink SE
PAR:GET
|
FR |
|
Canon Inc
OTC:CAJPY
|
JP |
Novan Inc
Operating Expenses
Novan Inc
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Novan Inc
F:6LUA
|
Operating Expenses
-$45.6m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Operating Expenses
-$31.1B
|
CAGR 3-Years
1%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-1%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Operating Expenses
-$17.7B
|
CAGR 3-Years
10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-5%
|
|
|
Pfizer Inc
NYSE:PFE
|
Operating Expenses
-$27.5B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-1%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Operating Expenses
-$26.2B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-5%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Operating Expenses
-$24.4B
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-8%
|
|
Novan Inc
Glance View
Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. The company is headquartered in Durham, North Carolina and currently employs 29 full-time employees. The company went IPO on 2016-09-21. The firm is engaged in researching, developing and marketing products for skin diseases. The firm is focused on dermatology and anti-infective therapies. Its technology platform leverages nitric oxide’s naturally occurring anti-viral, anti-bacterial, anti-fungal, and immunomodulatory mechanisms of action to treat a range of diseases. The firm has clinical-stage dermatology and anti-infective drug candidates with multi-factorial (SB204), anti-viral (SB206), anti-fungal (SB208), and anti-inflammatory (SB414) mechanisms of action. The Company’s lead product candidate is SB206, which is a topical gel with anti-viral properties for the treatment of viral skin infections, with focus on molluscum contagiosum. The firm is exploring the potential of its NITRICIL technology as a potential treatment option for COVID-19, targeting the reduction of viral shedding and transmission.
See Also
What is Novan Inc's Operating Expenses?
Operating Expenses
-45.6m
USD
Based on the financial report for Dec 31, 2022, Novan Inc's Operating Expenses amounts to -45.6m USD.
What is Novan Inc's Operating Expenses growth rate?
Operating Expenses CAGR 5Y
-4%
Over the last year, the Operating Expenses growth was -39%. The average annual Operating Expenses growth rates for Novan Inc have been -9% over the past three years , -4% over the past five years .
